Systemic Lupus Erythematous SLE Drugs Market Overview (2022-2032)

[250 Pages Report] The systemic lupus erythematosus (SLE) drugs market is projected to record a CAGR of 5% during the forecast period, up from US$ 183.3 Billion in 2020, to reach a valuation of US$ 329.18 Billion by 2032.

The systemic lupus erythematosus (SLE) drugs market is anticipated to show promising growth prospects owing to the prevalence of autoimmune diseases, particularly systemic lupus erythematosus (SLE).

Attributes Details
Systemic Lupus Erythematosus (SLE) Drugs Market Value (2020) US$ 183.3 Billion
Systemic Lupus Erythematosus (SLE) Drugs Market (2032) US$ 329.18 Billion
CAGR (2022 to 2032) 5%

Sales of systemic lupus erythematosus (SLE) drugs is expected to rise with the introduction of novel biological therapies in the development pipeline. In addition to this, demand for systemic lupus erythematosus (SLE) drugs is rising due to the rising frequency of autoimmune illnesses, notably systemic lupus erythematosus (SLE).

This factor is anticipated to significantly influence the systemic lupus erythematosus (SLE) drugs market, as over 50% of SLE patients have lupus nephritis. 

Some new potential medications in Phase III studies are also projected to contribute to the growth of the systemic lupus erythematosus (SLE) drugs market share.

Some of the key systemic lupus erythematosus (SLE) drugs trends promoting the demand for systemic lupus erythematosus (SLE) drugs market include clinicians only administering biologics when two or more non-biologic immunosuppressants have failed to ameliorate a patient's disease activity.

Several nations have developed payment schemes based on these criteria, which greatly boosted the sales of systemic lupus erythematosus (SLE) drugs. 

In developed nations, demand for systemic lupus erythematosus (SLE) drugs is higher due to stronger healthcare infrastructure and coverage availability. In underdeveloped regions, high costs and a lack of government-funded coverage limit access to biologics.

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

What are the Key Contributors to the Systemic Lupus Erythematosus (SLE) Drugs Market Share?

The global market for systemic lupus erythematosus (SLE) drugs is expected to expand due to the rising frequency of autoimmune illnesses, notably systemic lupus erythematosus (SLE). The development of newer SLE medicines increased availability of biosimilar pharmaceuticals, and increased support for developing research areas for new drug molecules are increasing the sales of systemic lupus erythematosus (SLE) drugs and propelling the global systemic lupus erythematosus (SLE) drugs market forward. 

Increased awareness of illness diagnosis and treatment and constant research and development procedures for innovative therapeutic molecules are major drivers of the global systemic lupus erythematosus (SLE) drugs. Furthermore, the safety and quality of systemic lupus erythematous controlling therapy may provide a hurdle to the sales of systemic lupus erythematosus (SLE) drugs. 

Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Which Region holds the Highest Growth Potential in the Systemic Lupus Erythematosus (SLE) Drugs Market?

Global systemic lupus erythematosus (SLE) drugs market growth is fast in the North American region and is estimated to project remarkable CAGR growth throughout the forecast period.

In North America, the SLE is more prevalent among Hispanics, Asians, and Native Americans, according to the Centers for Disease Control and Prevention (CDC). It is anticipated that this factor will boost the demand for systemic lupus erythematosus (SLE) drugs in the region.

The second-largest and fastest-growing systemic lupus erythematosus (SLE) drugs market is Europe and is projected to reach nearly US$ 550 Mn and register a double-digit CAGR due to the higher prevalence of SLE in Europe. According to the Lupus Journal article, among the European countries, Sweden, Iceland, and Spain recorded the highest sales of systemic lupus erythematosus (SLE) drugs.

This is expected to be the primary driver for global systemic lupus erythematous drugs market growth in the US, France, Germany, Italy, Spain, the UK and Japan. Benlysta will lead sales of systemic lupus erythematosus (SLE) drugs in coming years because of its excellent safety profile as well as proven efficacy in clinical trials. 

Who are the Key Players in the Systemic Lupus Erythematosus (SLE) Drugs Market?

The key players in the global systemic lupus erythematous drugs market are Anthera Pharmaceuticals BMS, GSK, ImmuPharma, Merck Serono, UCB, Amgen, HGS, Immunomedics, Johnson and Johnson, MedImmune, Sanofi, Teva Pharmaceutical Industries.

Recent Developments

  • Hydroxychloroquine, the last drug, was approved by the FDA in 1955 for SLE treatment. 
  • Recently, a drug called belimumab was approved by FDA after 50 years long gap specifically for SLE, on March 9, 2011. It is the first-ever targeted biological drug for the treatment of SLE patients developed by Human Genome Sciences Inc. 
  • In collaboration with GlaxoSmithKline, Benlysta is anticipated to lead systemic lupus erythematosus (SLE) drugs market sales in coming years because of its excellent safety profile as well as proven efficacy in clinical trials. 
  • NSAIDs such as Ibuprofen and aspirin are widely prescribed drugs for suppressing symptoms of SLE.

Immunosuppressants by Roche (CellCept (Mycophenolate mofetil), by Novartis (Neoral (Cyclosporine)), by GSK (Imuran (Azathioprine)) are also commonly prescribed for SLE treatment

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Scope of Report

Report Attribute Details
Growth rate CAGR of 5% from 2022 to 2032
Base year for estimation 2021
Historical data 2015 to 2020
Forecast period 2022 to 2032
Quantitative units Revenue in USD Million, volume in kilotons, and CAGR from 2022 to 2032
Report coverage Revenue forecast, volume forecast, company ranking, competitive landscape, growth factors, and trends, Pricing Analysis,
Segments covered Drug Classes, Route of Administration, region
Regional scope North America; Western Europe; Eastern Europe; Middle East; Africa; ASEAN; South Asia; Rest of Asia; Australia and New Zealand
Country scope USA, Canada, Mexico, Germany, UK, France, Italy, Spain, Russia, Belgium, Poland, Czech Republic, China, India, Japan, Australia, Brazil, Argentina, Colombia, Saudi Arabia, UAE, Iran, South Africa
Key companies profiled Anthera Pharmaceuticals BMS; GSK; ImmuPharma; Merck Serono; UCB; Amgen; HGS; Immunomedics; Johnson and Johnson; MedImmune; Sanofi; Teva Pharmaceutical Industries.
Customization scope Free report customization (equivalent to up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options Avail customized purchase options to meet your exact research needs.

Key Segments

By Drug Classes:

  • NSAIDs
  • Corticosteroids
  • Antimalarials
  • Immunosuppresants
  • Biologics

By Route of Administration:

  • Oral
  • Intravenous
  • Subcutaneous

By Region:

  • North America
  • Latin America
  • Asia Pacific
  • MEA
  • Europe

Frequently Asked Questions

What is the Growth Outlook for the Systemic Lupus Erythematosus (SLE) Drugs Market?

The systemic lupus erythematous (SLE) drugs market is likely to register a CAGR of 5% during the forecast period (2022-2032).

Who are the Key Players in the Systemic Lupus Erythematosus (SLE) Drugs Market?

Key players holding substantial systemic lupus erythematous (SLE) drugs market share include Anthera Pharmaceuticals BMS, GSK, ImmuPharma, Merck Serono, UCB, Amgen, HGS, Immunomedics, Johnson and Johnson, MedImmune, Sanofi, Teva Pharmaceutical Industries.

What is the Future of the Systemic Lupus Erythematosus (SLE) Drugs Market?

As per the analysis, the systemic lupus erythematous (SLE) drugs market is likely to be US$ 329 Bn by 2032.

Which is the Key Driver in the Systemic Lupus Erythematosus (SLE) Drugs Market?

Demand for systemic lupus erythematous (SLE) drugs is likely to rise owing to the prevalence of autoimmune diseases, particularly systemic lupus erythematosus (SLE).

Table of Content

1. Executive Summary

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Investment Feasibility Matrix

    3.5. PESTLE and Porter’s Analysis

    3.6. Regulatory Landscape

        3.6.1. By Key Regions

        3.6.2. By Key Countries

    3.7. Regional Parent Market Outlook

4. Global Market Analysis 2017-2021 and Forecast, 2022-2032

    4.1. Historical Market Size Value (US$ Mn) Analysis, 2017-2021

    4.2. Current and Future Market Size Value (US$ Mn) Projections, 2022-2032

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Market Analysis 2017-2021 and Forecast 2022-2032, By Molecule Type

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ Mn) Analysis By Molecule Type, 2017-2021

    5.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Molecule Type, 2022-2032

        5.3.1. Corticosteroids

        5.3.2. Non-Steroidal Anti-inflammatory Drugs

        5.3.3. Disease-Modifying Anti-Rheumatic Drugs

        5.3.4. Antimalarial Drugs

        5.3.5. BLyS-specific Inhibitors or Monoclonal Antibodies

        5.3.6. Immunosuppressive Agents/Immune Modulators

        5.3.7. Anticoagulants

    5.4. Y-o-Y Growth Trend Analysis By Molecule Type, 2017-2021

    5.5. Absolute $ Opportunity Analysis By Molecule Type, 2022-2032

Deep-dive segmentation will be available in the sample on request

6. Global Market Analysis 2017-2021 and Forecast 2022-2032, By Distribution Channel

    6.1. Introduction / Key Findings

    6.2. Historical Market Size Value (US$ Mn) Analysis By Distribution Channel, 2017-2021

    6.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Distribution Channel, 2022-2032

        6.3.1. Hospital Pharmacies

        6.3.2. Drug Stores

        6.3.3. Pharmacies

    6.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2017-2021

    6.5. Absolute $ Opportunity Analysis By Distribution Channel, 2022-2032

Deep-dive segmentation will be available in the sample on request

7. Global Market Analysis 2017-2021 and Forecast 2022-2032, By Region

    7.1. Introduction

    7.2. Historical Market Size Value (US$ Mn) Analysis By Region, 2017-2021

    7.3. Current Market Size Value (US$ Mn) Analysis and Forecast By Region, 2022-2032

        7.3.1. North America

        7.3.2. Latin America

        7.3.3. Europe

        7.3.4. East Asia

        7.3.5. South Asia & Pacific

        7.3.6. MEA

    7.4. Market Attractiveness Analysis By Region

8. North America Market Analysis 2017-2021 and Forecast 2022-2032, By Country

    8.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021

    8.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032

        8.2.1. By Country

            8.2.1.1. U.K.

            8.2.1.2. Canada

        8.2.2. By Molecule Type

        8.2.3. By Distribution Channel

    8.3. Market Attractiveness Analysis

        8.3.1. By Country

        8.3.2. By Molecule Type

        8.3.3. By Distribution Channel

    8.4. Key Takeaways

9. Latin America Market Analysis 2017-2021 and Forecast 2022-2032, By Country

    9.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021

    9.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032

        9.2.1. By Country

            9.2.1.1. Brazil

            9.2.1.2. Mexico

            9.2.1.3. Rest of Latin America

        9.2.2. By Molecule Type

        9.2.3. By Distribution Channel

    9.3. Market Attractiveness Analysis

        9.3.1. By Country

        9.3.2. By Molecule Type

        9.3.3. By Distribution Channel

    9.4. Key Takeaways

10. Europe Market Analysis 2017-2021 and Forecast 2022-2032, By Country

    10.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021

    10.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032

        10.2.1. By Country

            10.2.1.1. Germany

            10.2.1.2. U.K.

            10.2.1.3. France

            10.2.1.4. Spain

            10.2.1.5. Italy

            10.2.1.6. Rest of Europe

        10.2.2. By Molecule Type

        10.2.3. By Distribution Channel

    10.3. Market Attractiveness Analysis

        10.3.1. By Country

        10.3.2. By Molecule Type

        10.3.3. By Distribution Channel

    10.4. Key Takeaways

11. East Asia Market Analysis 2017-2021 and Forecast 2022-2032, By Country

    11.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021

    11.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032

        11.2.1. By Country

            11.2.1.1. China

            11.2.1.2. Japan

            11.2.1.3. South Korea

        11.2.2. By Molecule Type

        11.2.3. By Distribution Channel

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Molecule Type

        11.3.3. By Distribution Channel

    11.4. Key Takeaways

12. South Asia & Pacific Market Analysis 2017-2021 and Forecast 2022-2032, By Country

    12.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021

    12.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032

        12.2.1. By Country

            12.2.1.1. India

            12.2.1.2. Thailand

            12.2.1.3. Indonesia

            12.2.1.4. Malaysia

            12.2.1.5. Singapore

            12.2.1.6. Australia

            12.2.1.7. New Zealand

            12.2.1.8. Rest of South Asia & Pacific

        12.2.2. By Molecule Type

        12.2.3. By Distribution Channel

    12.3. Market Attractiveness Analysis

        12.3.1. By Country

        12.3.2. By Molecule Type

        12.3.3. By Distribution Channel

    12.4. Key Takeaways

13. MEA Market Analysis 2017-2021 and Forecast 2022-2032, By Country

    13.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021

    13.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032

        13.2.1. By Country

            13.2.1.1. GCC Countries

            13.2.1.2. South Africa

            13.2.1.3. Israel

            13.2.1.4. Rest of MEA

        13.2.2. By Molecule Type

        13.2.3. By Distribution Channel

    13.3. Market Attractiveness Analysis

        13.3.1. By Country

        13.3.2. By Molecule Type

        13.3.3. By Distribution Channel

    13.4. Key Takeaways

14. Key Countries Market Analysis

    14.1. U.K.

        14.1.1. Pricing Analysis

        14.1.2. Market Share Analysis, 2021

            14.1.2.1. By Molecule Type

            14.1.2.2. By Distribution Channel

    14.2. Canada

        14.2.1. Pricing Analysis

        14.2.2. Market Share Analysis, 2021

            14.2.2.1. By Molecule Type

            14.2.2.2. By Distribution Channel

    14.3. Brazil

        14.3.1. Pricing Analysis

        14.3.2. Market Share Analysis, 2021

            14.3.2.1. By Molecule Type

            14.3.2.2. By Distribution Channel

    14.4. Mexico

        14.4.1. Pricing Analysis

        14.4.2. Market Share Analysis, 2021

            14.4.2.1. By Molecule Type

            14.4.2.2. By Distribution Channel

    14.5. Germany

        14.5.1. Pricing Analysis

        14.5.2. Market Share Analysis, 2021

            14.5.2.1. By Molecule Type

            14.5.2.2. By Distribution Channel

    14.6. U.K.

        14.6.1. Pricing Analysis

        14.6.2. Market Share Analysis, 2021

            14.6.2.1. By Molecule Type

            14.6.2.2. By Distribution Channel

    14.7. France

        14.7.1. Pricing Analysis

        14.7.2. Market Share Analysis, 2021

            14.7.2.1. By Molecule Type

            14.7.2.2. By Distribution Channel

    14.8. Spain

        14.8.1. Pricing Analysis

        14.8.2. Market Share Analysis, 2021

            14.8.2.1. By Molecule Type

            14.8.2.2. By Distribution Channel

    14.9. Italy

        14.9.1. Pricing Analysis

        14.9.2. Market Share Analysis, 2021

            14.9.2.1. By Molecule Type

            14.9.2.2. By Distribution Channel

    14.10. China

        14.10.1. Pricing Analysis

        14.10.2. Market Share Analysis, 2021

            14.10.2.1. By Molecule Type

            14.10.2.2. By Distribution Channel

    14.11. Japan

        14.11.1. Pricing Analysis

        14.11.2. Market Share Analysis, 2021

            14.11.2.1. By Molecule Type

            14.11.2.2. By Distribution Channel

    14.12. South Korea

        14.12.1. Pricing Analysis

        14.12.2. Market Share Analysis, 2021

            14.12.2.1. By Molecule Type

            14.12.2.2. By Distribution Channel

    14.13. India

        14.13.1. Pricing Analysis

        14.13.2. Market Share Analysis, 2021

            14.13.2.1. By Molecule Type

            14.13.2.2. By Distribution Channel

    14.14. Thailand

        14.14.1. Pricing Analysis

        14.14.2. Market Share Analysis, 2021

            14.14.2.1. By Molecule Type

            14.14.2.2. By Distribution Channel

    14.15. Indonesia

        14.15.1. Pricing Analysis

        14.15.2. Market Share Analysis, 2021

            14.15.2.1. By Molecule Type

            14.15.2.2. By Distribution Channel

    14.16. Malaysia

        14.16.1. Pricing Analysis

        14.16.2. Market Share Analysis, 2021

            14.16.2.1. By Molecule Type

            14.16.2.2. By Distribution Channel

    14.17. Singapore

        14.17.1. Pricing Analysis

        14.17.2. Market Share Analysis, 2021

            14.17.2.1. By Molecule Type

            14.17.2.2. By Distribution Channel

    14.18. Australia

        14.18.1. Pricing Analysis

        14.18.2. Market Share Analysis, 2021

            14.18.2.1. By Molecule Type

            14.18.2.2. By Distribution Channel

    14.19. New Zealand

        14.19.1. Pricing Analysis

        14.19.2. Market Share Analysis, 2021

            14.19.2.1. By Molecule Type

            14.19.2.2. By Distribution Channel

    14.20. GCC Countries

        14.20.1. Pricing Analysis

        14.20.2. Market Share Analysis, 2021

            14.20.2.1. By Molecule Type

            14.20.2.2. By Distribution Channel

    14.21. South Africa

        14.21.1. Pricing Analysis

        14.21.2. Market Share Analysis, 2021

            14.21.2.1. By Molecule Type

            14.21.2.2. By Distribution Channel

    14.22. Israel

        14.22.1. Pricing Analysis

        14.22.2. Market Share Analysis, 2021

            14.22.2.1. By Molecule Type

            14.22.2.2. By Distribution Channel

15. Market Structure Analysis

    15.1. Competition Dashboard

    15.2. Competition Benchmarking

    15.3. Market Share Analysis of Top Players

        15.3.1. By Regional

        15.3.2. By Molecule Type

        15.3.3. By Distribution Channel

16. Competition Analysis

    16.1. Competition Deep Dive

        16.1.1. Anthera Pharmaceuticals

            16.1.1.1. Overview

            16.1.1.2. Product Portfolio

            16.1.1.3. Profitability by Market Segments

            16.1.1.4. Sales Footprint

            16.1.1.5. Strategy Overview

                16.1.1.5.1. Marketing Strategy

        16.1.2. GlaxoSmithKline Pharmaceuticals Limited

            16.1.2.1. Overview

            16.1.2.2. Product Portfolio

            16.1.2.3. Profitability by Market Segments

            16.1.2.4. Sales Footprint

            16.1.2.5. Strategy Overview

                16.1.2.5.1. Marketing Strategy

        16.1.3. ImmuPharma PLC

            16.1.3.1. Overview

            16.1.3.2. Product Portfolio

            16.1.3.3. Profitability by Market Segments

            16.1.3.4. Sales Footprint

            16.1.3.5. Strategy Overview

                16.1.3.5.1. Marketing Strategy

        16.1.4. Merck Serono

            16.1.4.1. Overview

            16.1.4.2. Product Portfolio

            16.1.4.3. Profitability by Market Segments

            16.1.4.4. Sales Footprint

            16.1.4.5. Strategy Overview

                16.1.4.5.1. Marketing Strategy

        16.1.5. Johnson & Johnson Private Limited

            16.1.5.1. Overview

            16.1.5.2. Product Portfolio

            16.1.5.3. Profitability by Market Segments

            16.1.5.4. Sales Footprint

            16.1.5.5. Strategy Overview

                16.1.5.5.1. Marketing Strategy

        16.1.6. Novartis AG

            16.1.6.1. Overview

            16.1.6.2. Product Portfolio

            16.1.6.3. Profitability by Market Segments

            16.1.6.4. Sales Footprint

            16.1.6.5. Strategy Overview

                16.1.6.5.1. Marketing Strategy

        16.1.7. MedImmune

            16.1.7.1. Overview

            16.1.7.2. Product Portfolio

            16.1.7.3. Profitability by Market Segments

            16.1.7.4. Sales Footprint

            16.1.7.5. Strategy Overview

                16.1.7.5.1. Marketing Strategy

        16.1.8. Sanofi

            16.1.8.1. Overview

            16.1.8.2. Product Portfolio

            16.1.8.3. Profitability by Market Segments

            16.1.8.4. Sales Footprint

            16.1.8.5. Strategy Overview

                16.1.8.5.1. Marketing Strategy

        16.1.9. Teva Pharmaceutical Industries

            16.1.9.1. Overview

            16.1.9.2. Product Portfolio

            16.1.9.3. Profitability by Market Segments

            16.1.9.4. Sales Footprint

            16.1.9.5. Strategy Overview

                16.1.9.5.1. Marketing Strategy

        16.1.10. HGS

            16.1.10.1. Overview

            16.1.10.2. Product Portfolio

            16.1.10.3. Profitability by Market Segments

            16.1.10.4. Sales Footprint

            16.1.10.5. Strategy Overview

                16.1.10.5.1. Marketing Strategy

17. Assumptions & Acronyms Used

18. Research Methodology

Recommendations

Healthcare

Injectable Drug Market

March 2024

REP-GB-15073

306 pages

Healthcare

General Anesthesia Drugs Market

September 2023

REP-GB-388

306 pages

Healthcare

Companion Animal Drugs Market

February 2023

REP-GB-1077

167 pages

Healthcare

Extended Release Drugs Market

June 2022

REP-GB-9581

250 pages

Explore Healthcare Insights

View Reports
Future Market Insights

Systemic Lupus Erythematous SLE Drugs Market

Schedule a Call